Drug Trial Radar · NCT00493870
TAC Versus TC for Adjuvant Breast Cancer
Last checked: Nov 20, 2026Latest source record: Mar 2, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,961
Actual
Start
May 29, 2007
Primary completion
May 31, 2015
Study completion Mar 30, 2020
Sponsor
- Lead sponsor
- US Oncology ResearchIndustry
- Sponsor type
- Industry
- Collaborators
- Sanofi
- First posted
- Jun 28, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this research study is to find out what effects (good and bad) TC or TAC has on early stage HER2- breast cancer.
Conditions
- Breast Cancer
Interventions
DocetaxelDrug
Docetaxel 75 mg/m2 IV over 1 hour on Day 1 followed by cyclophosphamide
DoxorubicinDrug
• Doxorubicin 50 mg/m2 IV push over 5-15 minutes via sidearm through a running IV line on Day 1, followed by cyclophosphamide 500 mg/m2 IV over 15-30 minutes on Day 1, followed by docetaxel 75 mg/m2 IV over 1 hour on Day 1. Administer pegfilgrastim 6 mg SC on Day 2 (or filgrastim 5 mcg/kg SC per standard of care).
CyclophosphamideDrug
600 mg/m2 IV over 15-30 minutes on Day 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- 3-year Invasive Disease-free Survival (IDFS) Among Analyzed ITT PatientsTime frame: 3 years from randomization into study
- 3-year Invasive Disease-free Survival (IDFS) Among Per-protocol PatientsTime frame: 3 years from randomization into study
Locations
95 sites in 1 country. Site status is shown where the registry gives one.
Birmingham Hematology and Oncology
Birmingham, Alabama
Hematology Oncology Associates
Phoenix, Arizona
Northern AZ Hematology Oncology Associates-AOA
Sedona, Arizona
Arizona Oncology Associates DBA HOPE
Tucson, Arizona
Central Hematology Oncology Medical Group, Inc.
Alhambra, California
Comprehensive Blood and Cancer Center
Bakersfield, California
St. Jude Hertiage Medical Group
Fullerton, California
Wilshire Oncology Medical Group
La Verne, California
Antelope Valley Cancer Center
Lancaster, California
Pacific Shores Medical Group
Long Beach, California
University of California-Los Angeles
Los Angeles, California
North Valley Hematology/Oncology Medical Group
Northridge, California
Ventura County Hematology-Oncology Specialist
Oxnard, California
SAMSUM Clinic
Santa Barbara, California
Santa Barabra Hematology Oncology Medical Group, Inc.
Santa Barbara, California
Central Coast Medical Oncology Corporation
Santa Maria, California
Rocky Mountain Cancer Center-Rose
Denver, Colorado
Flordia Cancer Specialist
Fort Myers, Florida
Melbourne Internal Medicine Associates
Melbourne, Florida
Advanced Medical Specialist
Miami, Florida
Florida Cancer Institute
New Port Richey, Florida
Ocala Oncology Center
Ocala, Florida
Cancer Centers of Florida, P.A.
Ocoee, Florida
Suburban Hematology-Oncology Associates, PC
Lawrenceville, Georgia
Northwest Georgia Oncology Centers, PC
Marietta, Georgia
Hematology Oncology Associates of IL
Chicago, Illinois
Cancer Care & Hematology Specialists of Chicagoland
Niles, Illinois
Central Indiana Cancer Centers
Indianapolis, Indiana
Hope Center
Terre Haute, Indiana
Kansas City Cancer Centers-Southwest
Overland Park, Kansas
Maryland Oncology Hematology, P.A.
Columbia, Maryland
Alliance Hematology Oncology PA
Westminster, Maryland
Minnesota Oncology Hematology, P.A.
Minneapolis, Minnesota
Missouri Cancer Associates
Columbia, Missouri
Arch Medical Services, Inc.
St Louis, Missouri
Comprehensive Cancer Center of Nevada
Henderson, Nevada
Hematology-Oncology Associates of NNJ, P.A.
Morristown, New Jersey
Southern New Mexico Cancer Center
Las Cruces, New Mexico
New Mexico Cancer Care Associates
Santa Fe, New Mexico
New York Oncology Hematology, P.C.
Albany, New York
Showing 40 of 95 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.